Relmada Therapeutics (NASDAQ:RLMD) Releases Earnings Results, Beats Estimates By $0.02 EPS

Relmada Therapeutics (NASDAQ:RLMD) posted its quarterly earnings data on Thursday. The company reported ($0.12) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.14) by $0.02, FiscalAI reports.

Here are the key takeaways from Relmada Therapeutics’ conference call:

• NDV-01’s phase II results showed that 12 of 14 evaluable patients remained in complete response at 18 months, including seven of eight in the BCG-unresponsive subgroup. However, two BCG-naive patients with T1 disease progressed to muscle-invasive cancer at month 15, and the company has not yet analyzed outcomes specifically for patients matching the planned phase III population.
• Relmada remains on track to file NDV-01’s IND by year-end 2026 and expects to begin the SPECTRUM phase III program after clearance; management said the first patient could be dosed in the first quarter of 2027 if clearance comes in a reasonable timeframe. SPECTRUM includes separate registrational pathways for BCG-unresponsive high-risk disease and low-grade, intermediate-risk disease.
• The company said it has optimized new manufacturing processes and completed GMP batches, with nine-week stability results so far within FDA requirements. Further stability data are still pending, although management said it expects to complete the IND filing by year-end.
• Relmada ended the quarter with $202.1 million in cash, cash equivalents, and short-term investments, which management expects to fund operations through 2029, including completion of the NDV-01 phase III studies.

Relmada Therapeutics Stock Down 2.1%

Shares of RLMD traded down $0.09 during mid-day trading on Friday, reaching $4.07. The company’s stock had a trading volume of 758,000 shares, compared to its average volume of 1,498,565. The business has a fifty day moving average of $3.77 and a 200 day moving average of $5.33. The company has a market cap of $434.25 million, a price-to-earnings ratio of -4.51 and a beta of 0.62. Relmada Therapeutics has a 1 year low of $3.07 and a 1 year high of $8.00.

Analysts Set New Price Targets

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of Relmada Therapeutics in a report on Monday, September 14th. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Relmada Therapeutics has an average rating of “Moderate Buy” and an average target price of $12.00.

Insider Activity at Relmada Therapeutics

In other Relmada Therapeutics news, CFO Maged Shenouda purchased 79,800 shares of the stock in a transaction dated Thursday, September 10th. The shares were acquired at an average price of $4.25 per share, for a total transaction of $339,150.00. Following the completion of the acquisition, the chief financial officer owned 1,000,000 shares of the company’s stock, valued at $4,250,000. This represents a 8.67% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 14.50% of the stock is currently owned by company insiders.

About Relmada Therapeutics

Relmada Therapeutics, Inc. is a clinical-stage biotechnology company developing investigational treatments for central nervous system disorders, with a focus on depression. The company’s work centers on advancing drug candidates through clinical research; it does not have an approved commercial product. Its best-known candidate, REL-1017 (esmethadone), is an oral compound that acts on NMDA receptors. Relmada has studied it as an add-on treatment for adults with major depressive disorder who have not responded adequately to existing antidepressants.